References
- 1. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet. 2008; 40(1): 17-22.
- 2. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene. 2006; 25(43): 5912-5919.
- 3. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999; 286(5449): 2528-2531.
- 4. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002; 71(2): 432-438.
- 5. Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, van Leeuwen FE, et al. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat. 2004; 83(1): 91-93.
- 6. Cybulski C, Huzarski T, Gorski B, Masojc B, Mier- zejewski M, Debniak T, et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res. 2004; 64(8): 2677-2679.
- 7. Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S, Lazjuk GI, Rogov YI, Dammann O, et al. Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer. 2005; 116(2): 263-266.
- 8. Dufault MR, Betz B, Wappenschmidt B, Hofmann W, Bandick K, Golla A, et al. Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer. 2004; 110(3): 320-325.
- 9. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006; 295(12): 1379-1388.
- 10. Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, et al. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat. 2007; 102(1): 119-122.
- 11. Liu C, Wang Y, Wang QS, Wang YJ. The CHEK2 I157T variant and breast cancer susceptibility: A systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012; 13(4): 1355-1360.
- 12. Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K, et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell. 1998; 93(3): 467-476.
- 13. Varon R, Seemanova E, Chrzanowska K, Hnateyko O, Piekutowska-Abramczuk D, Krajewska- Walasek M, et al. Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations. Eur J Hum Genet. 2000; 8(11): 900-902.
- 14. Bogdanova N, Feshchenko S, Schurmann P, Waltes R, Wieland B, Hillemanns P, et al. Nijmegen breakage syndrome mutations and risk of breast cancer. Int J Cancer. 2008; 122(4): 802-806.
- 15. Maleva I, Madjunkova S, Bozhinovski G, Smickova E, Kondov G, Spiroski Z, et al. Genetic variation of the brca1 and brca2 genes in Macedonian patients. Balkan J Med Genet. 2012; 15(Suppl): 81-85.
- 16. de Jong MM, van der Graaf WTA, Nolte IM, Te Meerman GJ, Oosterwijk JC, van der Steege G, et al. Increased CHEK2 1100delC genotype frequency (also) in unselected breast cancer patients (conference abstract). American Society of Clinical Oncology Annual Meeting Proceedings (Post- Meeting Edition), New Orleans, LA, USA, June 5-8 2004. J Clin Oncol. 2004; 22(14S): 9536.
- 17. Einarsdottir K, Humphreys K, Bonnard C, Palmgren J, Iles MM, Sjolander A, et al. Linkage disequilibrium mapping of CHEK2: Common variation and breast cancer risk. PLoS Med. 2006; 3(6): e168. doi: 10.1371/ journal. pmed.0030168.
- 18. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol. 2007; 25(1): 57-63.
- 19. Mateus Pereira LH, Sigurdson AJ, Doody MM, Pineda MA, Alexander BH, Greene MH, et al. CHEK2: 1100delC and female breast cancer in the United States. Int J Cancer. 2004; 112(3): 541-543.
- 20. Rashid MU, Jakubowska A, Justenhoven C, Harth V, Pesch B, Baisch C, et al. German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. Eur J Cancer. 2005; 41(18): 2896-2903.
- 21. Kleibl Z, Novotny J, Bezdickova D, Malik R, Klei-blova P, Foretova L, et al. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Res Treat. 2005; 90(2): 165-167.